PuSH - Publikationsserver des Helmholtz Zentrums München

90 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
1.
Clemmensen, C. et al.: Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. Nat. Rev. Endocrinol. 15, 90-104 (2019)
2.
Jall, S. et al.: Pirt deficiency has subtle female-specific effects on energy and glucose metabolism in mice. Mol. Metab. 23, 75-81 (2019)
3.
Khajavi, N.* et al.: Tri-agonist-induced PLC activation is associated with robust insulin secretion from murine islets. Naunyn-Schmiedebergs Arch. Pharmakol. 392, S35-S35 (2019)
4.
Müller, T.D. & Tschöp, M.H.: Glukagon, das vergessene Hormon. Diabetologe 15, 177-184 (2019)
5.
Niu, L.* et al.: Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol. Syst. Biol. 15:e8793 (2019)
6.
Al-Massadi, O.* ; Müller, T.D. ; Tschöp, M.H. ; Diéguez, C.* & Nogueiras, R.*: Ghrelin and LEAP-2: Rivals in energy metabolism. Trends Pharmacol. Sci. 39, 685-694 (2018)
7.
Brandt, S. ; Götz, A. ; Tschöp, M.H. & Müller, T.D.: Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides 100, 190-201 (2018)
8.
Brandt, S. ; Kleinert, M. ; Tschöp, M.H. & Müller, T.D.: Are peptide conjugates the golden therapy against obesity? J. Endocrinol. 238, R109-R119 (2018)
9.
Brandt, S. ; Müller, T.D. ; DiMarchi, R.D.* ; Tschöp, M.H. & Stemmer, K.: Peptide-based multi-agonists: A new paradigm in metabolic pharmacology. J. Intern. Med. 284, 581-602 (2018)
10.
Clemmensen, C. et al.: Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes. Nat. Commun. 9:4304 (2018)
11.
Clemmensen, C. et al.: Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes (vol 9, 4304, 2018). Nat. Commun. 9:4975 (2018)
12.
Giuranna, J.* et al.: The effect of SH2B1 variants on expression of leptin- and insulin-induced pathways in murine hypothalamus. Obes. Facts 11, 93-108 (2018)
13.
Hoffmann, V.* et al.: Effects of placebo interventions on subjective and objective markers of appetite-a randomized controlled trial. Front. Psychiatr. 9:706 (2018)
14.
Huang, J.* et al.: Adipocyte p62/SQSTM1 suppresses tumorigenesis through opposite regulations of metabolism in adipose tissue and tumor. Cancer Cell 33, 770-784.e6 (2018)
15.
Khajavi, N.* et al.: An incretin-based tri-agonist promotes superior insulin secretion from murine pancreatic islets via PLC activation. Cell. Signal. 51, 13-22 (2018)
16.
Kleinert, M. et al.: Animal models of obesity and diabetes mellitus. Nat. Rev. Endocrinol. 14, 140-162 (2018)
17.
Mueller, K.M.* et al.: Erratum. Adipocyte glucocorticoid Rrceptor deficiency attenuates aging- and HFD-induced obesity and impairs the feeding-fasting transition. Diabetes 2017;66:272-286. Diabetes 67, 343-344 (2018)
18.
Müller, T.D. ; Clemmensen, C. ; Finan, B. ; DiMarchi, R.D.* & Tschöp, M.H.: Anti-obesity therapy: From rainbow pills to polyagonists. Pharmacol. Rev. 70, 712-746 (2018)
19.
Poher, A.-L. ; Tschöp, M.H. & Müller, T.D.: Ghrelin regulation of glucose metabolism. Peptides 100, 236-242 (2018)
20.
Renner, S.* et al.: Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs. Mol. Metab., accepted (2018)